Results 241 to 250 of about 257,683 (336)

Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer

open access: yesInvestigational new drugs, 2016
S. Kummar   +12 more
semanticscholar   +1 more source

Insights into Non‐Classic Primary Bone Sarcomas in Children, Adolescents, and Young Adults: A French Descriptive Study

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Bone sarcomas other than osteosarcoma, chondrosarcoma, and Ewing sarcoma represent a challenge in care because they are uncommon, especially in children, adolescents, and young adults (AYA). Methods We conducted a retrospective review of patients aged 0–25 years treated for non‐osteosarcoma, non‐chondrosarcoma, non‐Ewing (and ...
Rafael Moisan   +16 more
wiley   +1 more source

Safranal Alleviates Cyclophosphamide Induced Testicular Toxicity in Rats. [PDF]

open access: yesFood Sci Nutr
Cellat M   +4 more
europepmc   +1 more source

Syndecan‐1 is Associated With Sinusoidal Obstruction Syndrome and Severe Acute Graft‐Versus‐Host Disease After Pediatric Hematopoietic Stem Cell Transplantation

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Endothelial damage may play a key role in several non‐infectious toxicities following hematopoietic stem cell transplantation (HSCT). We explored damage to the endothelial glycocalyx in 113 children undergoing HSCT by measuring syndecan‐1 plasma levels.
Denise Elbæk Horan   +6 more
wiley   +1 more source

Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer

open access: yesClinical Cancer Research, 2015
S. Kummar   +22 more
semanticscholar   +1 more source

Thiostrepton Suppresses the Progression of Rhabdomyosarcoma by Inhibiting the PI3K‐AKT Signaling Pathway

open access: yesPediatric Discovery, EarlyView.
The study establish TST as a multi‐mechanism PI3K‐AKT inhibitor for refractory RMS while validating Cmap‐driven drug repurposing for pediatric oncology. ABSTRACT Rhabdomyosarcoma (RMS), the most common pediatric soft tissue sarcoma with 5‐year survival below 30% in high‐risk/metastatic cases, was investigated through integrated bioinformatics analysis (
Yu Wang   +9 more
wiley   +1 more source

Impact of maintenance treatment on male gonadal function in patients treated for localized rhabdomyosarcoma in RMS2005 trial in France. [PDF]

open access: yesCancer
Rossillon L   +20 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy